A European partner in life science

Our vision is to improve people's lives by being a leading, value-adding partner in life science

Annual Report 2023

Share price


Press Releases


  • Interim report 1 Jan - 31 Mar 2024

    Investors, analysts and the media are invited to a video conference where CEO Fredrik Dalborg and CFO Christina Rubenhag will present the interim report. The presentation will be in English and take about 20 minutes, after which there will be an opportunity to ask questions. It will be recorded and made available online.

    The report is released Wednesday, April 24, 2024 at 07.45 a.m
    Video conference at 9:00 a.m

    Christina Rubenhag Fredrik Dalborg 2023
  • AddLife General Meeting 2024

    General meeting
    Adobestock 308561351
  • Organic growth at record level in 2023

    The record-breaking organic growth in 2023 validates the successful long-term positioning of AddLife for post-pandemic market conditions. It also shows the health and successful development of companies within the AddLife family, including both long-standing members and recent additions.

    Fredrik Dalborg VD Addlife 2023

Our business areas



In the Medtech business area, the subsidiaries offer products and services in the field of medical technology, as well as assistive equipment for use in homecare. Medtech’s offering mainly focuses on public funded health care, homecare and social care in Europe.

Read more


The Labtech business area provides products, solutions and services in fields such as diagnostics, biomedical research and laboratory analysis. Customers include hospitals, research laboratories, pharmaceutical companies, and food industry groups, primarily in the Nordics and rest of Europe.

Read more

Join the AddLife group

Do you have a life science company with opportunities to grow? We offer an attractive option with a decentralized business model where we combine the strength of a large enterprise with the dedication and business skills of an entrepreneur. As an AddLife subsidiary you are responsible for your business activities within the AddLife requirements for growth, profitability and sustainable development.


News from our subsidiaries

Euroclone Q4 2023
02 February 2024
Euroclone serves science through innovation

Euroclone´s mission is to serve science through innovation. This is represented by searching around the globe all innovation available in the market that represents new frontiers for Biomedical research.

22 January 2024 | triolab oy
Association supporting healthcare

Sailab – MedTech Finland is an association that, together with its member companies, helps the Finnish healthcare system produce the best treatment solutions.

13 January 2024 | Zafe
Smart teknik ger bättre vård

Kristianstadbladet skriver om Zafes tekniska trygghetslösningar för vården.

01 January 2024 | Biomedica Italia
The business unit of the Surgery Division of Euroclone Spa merges into Biomedica Italia Srl.

Today, the branch of Euroclone Spa specializing in the distribution of surgical products merges into Biomedica Italia Srl, another company in the Addlife group.

See all news

Sustainability for AddLife

Sustainability is a central part of AddLife's vision to improve people's life by being a leading, value adding provider in life science. AddLife´s approach to sustainability is identified through three impact areas where we can have the greatest contribution to a long-term lasting business and society.

Adobestock 300716540